Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $21.3 million.

  • Axsome Therapeutics' Cash from Financing Activities fell 3005.1% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.3 million, marking a year-over-year increase of 12783.87%. This contributed to the annual value of $57.8 million for FY2024, which is 8252.64% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Cash from Financing Activities of $21.3 million as of Q3 2025, which was down 3005.1% from $34.5 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Cash from Financing Activities registered a high of $246.1 million during Q2 2023, and its lowest value of -$1.2 million during Q1 2024.
  • Moreover, its 4-year median value for Cash from Financing Activities was $30.4 million (2024), whereas its average is $50.6 million.
  • The largest annual percentage gain for Axsome Therapeutics' Cash from Financing Activities in the last 5 years was 71230000.0% (2024), contrasted with its biggest fall of 10230.19% (2024).
  • Axsome Therapeutics' Cash from Financing Activities (Quarter) stood at $1.1 million in 2022, then tumbled by 100.19% to -$2000.0 in 2023, then skyrocketed by 712300.0% to $14.2 million in 2024, then soared by 49.31% to $21.3 million in 2025.
  • Its Cash from Financing Activities was $21.3 million in Q3 2025, compared to $34.5 million in Q2 2025 and $29.3 million in Q1 2025.